• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

    3/26/25 5:15:58 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SLNO alert in real time by email

    First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome

    Management to host conference call and webcast today, March 26th, at 5:30pm ET

    REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025.

    "The approval of VYKAT XR is a significant milestone for Soleno and, most importantly, for the PWS community who have had no options to treat the most disruptive aspect of this disease," said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno. "We are deeply grateful to the many individuals with PWS, their caregivers and clinical sites who participated in our trials, the advocacy groups, including FPWR and PWSA | USA, the advocates who have tirelessly supported the approval of VYKAT XR, the FDA for a collaborative review process, and our employees who have been committed to delivering VYKAT XR to those with PWS."

    "The FDA approval of VYKAT XR is an incredible achievement for the entire PWS community," said Jennifer Miller, M.D., Professor of Pediatric Endocrinology at the University of Florida, Gainesville, who specializes in treating children and adults with PWS and is a principal investigator in the VYKAT XR clinical development program. "I am excited to have VYKAT XR available to help treat hyperphagia, which is the most life-limiting aspect of PWS. Families of people with PWS have been prisoners in their own homes because of the need to provide constant, eyes-on supervision 24/7 with access to food being completely restricted."

    "Today marks a historic day for the PWS community. The FDA's approval of VYKAT XR represents a monumental step forward in addressing the longstanding unmet needs of individuals living with PWS and their families," said Stacy Ward, Chief Executive Officer of the Prader-Willi Syndrome Association | USA. "Our families experience the constant and disruptive challenges of hyperphagia, and VYKAT XR offers hope to so many."

    "This approval is a testament to the power of persistence, science, and advocacy," said Susan Hedstrom, Executive Director of the Foundation for Prader-Willi Research. "For years, families and researchers have worked towards a treatment option that truly addresses the complexities of PWS. Today, we take a major step forward in changing the future for individuals navigating hyperphagia associated with PWS."

    The FDA approval of VYKAT XR was based on an adequate and well-controlled study and safety data from the comprehensive clinical development program. Efficacy was established during the 16-week randomized withdrawal study period of Study 2-RWP (Study C602-RWP), a Phase 3 multi-center, randomized, double-blind, placebo-controlled trial. Individuals randomized to switch to placebo demonstrated a statistically significant worsening of hyperphagia compared with individuals who remained on VYKAT XR. Prior to participating in the randomized withdrawal period, all individuals received double-blind and/or open-label VYKAT XR for a mean duration of 3.3 years.

    VYKAT XR has a well-established safety profile with over four years of data across four double-blind and/or open label studies. The primary safety analyses are based on Study 1 (Study C601) and the most common adverse reactions occurring in greater than or equal to 10% of individuals receiving VYKAT XR and at 2% greater than placebo included hypertrichosis, edema, hyperglycemia and rash.

    Patient Support for Accessing VYKAT XR

    Today, Soleno has launched Soleno OneTM, a comprehensive patient support program. Information about the program is available at VykatXR.com. The Soleno One team can be reached toll-free at 1-(833)-SOLENO-1 (1-833-765-3661) from 8 a.m. to 8 p.m. ET Monday through Friday. Healthcare providers who want to submit prescriptions can visit VykatXRHCP.com to complete the Start Form that initiates the process for accessing treatment.

    Conference Call and Webcast Information

    Soleno management will host an investor conference call and webcast with slides to discuss the FDA's approval of VYKAT XR (diazoxide choline) extended-release tablets today, March 26th, at 5.30pm ET. Details can be found below:

      
    Conference call details:Toll-free: 1-877-423-9813
     International: 1-201-689-8573
     Conference ID: 13752679
    Call me™ (avoids waiting for an operator):Click here
    Webcast:Click here
      

    A replay of the call will be available following the call on the Investors section of the Soleno website.

    About Prader-Willi Syndrome

    Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The defining symptom of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense persistent sensation of hunger accompanied by food preoccupations, an extreme drive to consume food, food-related behavior problems, and a lack of normal satiety, which can severely diminish the quality of life for individuals with PWS and their families. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease.  

    INDICATION

    VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).

    IMPORTANT SAFETY INFORMATION

    Contraindications

    Use of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.

    Warnings and Precautions

    Hyperglycemia

    Hyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia.

    Risk of Fluid Overload

    Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.

    Adverse Reactions

    The most common adverse reactions (incidence ≥10% and at least 2% greater than placebo) included hypertrichosis, edema, hyperglycemia, and rash.

    Please see the full Prescribing Information, including Medication Guide.

    About Soleno Therapeutics, Inc.

    Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of commercialization of VYKAT XR for the treatment of hyperphagia in individuals with PWS, the potential market opportunity for VYKAT XR and the ability of VYKAT XR to address the unmet needs of the PWS community. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    Investor Contact:

    Brian Ritchie

    LifeSci Advisors, LLC

    212-915-2578

    Media Contact:

    [email protected]



    Primary Logo

    Get the next $SLNO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLNO

    DatePrice TargetRatingAnalyst
    3/5/2025$74.00Buy
    Stifel
    12/2/2024$74.00Buy
    Stifel
    12/2/2024$72.00Outperform
    Robert W. Baird
    9/3/2024$70.00Buy
    H.C. Wainwright
    5/10/2024$72.00Outperform
    Robert W. Baird
    2/5/2024$93.00Overweight
    Piper Sandler
    1/23/2024$63.00Buy
    Stifel
    11/21/2023$40.00Buy
    Guggenheim
    More analyst ratings

    $SLNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel resumed coverage on Soleno Therapeutics with a new price target

      Stifel resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $74.00

      3/5/25 7:44:16 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stifel reiterated coverage on Soleno Therapeutics with a new price target

      Stifel reiterated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $74.00

      12/2/24 10:10:09 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Robert W. Baird reiterated coverage on Soleno Therapeutics with a new price target

      Robert W. Baird reiterated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $72.00

      12/2/24 8:19:44 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

      REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets (previously referred to as DCCR) for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA). "The validation of our MAA represents the next significant milestone in our mission to deliver this important therapy to the broad PWS communit

      5/22/25 5:32:41 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics to Participate in Upcoming June Conferences

      REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in June: Jefferies Global Healthcare ConferencePresentation Date: Wednesday, June 4, 2025 at 10:30 AM ETPresentation Format: Corporate PresentationWebcast: Here Goldman Sachs 46th Healthcare ConferencePresentation Date: Tuesday, June 10, 2025 at 8:40 AM ETPresentation Format: Corporate PresentationWebcast: Here A replay of both events will be available in the Investors section on the Company's website at www.sol

      5/21/25 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome

      REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, at the Pediatric Endocrine Society (PES) Annual Meeting 2025, which was held May 15-18 in National Harbor, Maryland, USA. The presentation showed that resumption of VYKAT XR treatment in participants with PWS following a 16-week randomized withdrawal was associated with significant improvements in both hyperphagia and behavioral symptoms. "We

      5/20/25 4:05:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Financials

    Live finance-specific insights

    See more
    • Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Corporate Highlights Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). Announced launch and commencement of pati

      5/7/25 4:01:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

      REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, May 7, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conferenc

      4/23/25 7:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

      First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). Soleno expects VYKAT XR to be available in the U.S. begin

      3/26/25 5:15:58 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

      SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      5/14/25 12:02:12 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SCHEDULE 13G filed by Soleno Therapeutics Inc.

      SCHEDULE 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      5/14/25 10:45:26 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Soleno Therapeutics Inc.

      10-Q - SOLENO THERAPEUTICS INC (0001484565) (Filer)

      5/7/25 4:13:45 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

      SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/19/24 9:44:27 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

      SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/14/24 4:30:58 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

      SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

      11/14/24 12:51:18 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Leadership Updates

    Live Leadership Updates

    See more

    $SLNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Soleno Therapeutics Set to Join Russell 3000® Index

      REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta

      6/4/24 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Strengthens Leadership Team with Key Appointments

      REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone

      1/24/24 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

      REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience. "Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board," said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. "His impressive track record, including in rare diseases, will b

      8/16/23 8:00:00 AM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Perceptive Advisors Llc bought $15,113,916 worth of shares (866,789 units at $17.44) (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      9/28/23 3:45:22 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $SLNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Hirano Patricia C sold $265,156 worth of shares (3,782 units at $70.11), decreasing direct ownership by 12% to 27,036 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      4/2/25 5:38:26 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Pauls Matthew exercised 5,937 shares at a strike of $4.60 and sold $424,797 worth of shares (5,937 units at $71.55) (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/31/25 7:24:33 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Officer Yen Kristen sold $6,376,789 worth of shares (95,500 units at $66.77) and exercised 40,638 shares at a strike of $4.97, decreasing direct ownership by 66% to 28,143 units (SEC Form 4)

      4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

      3/31/25 7:23:00 PM ET
      $SLNO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care